References
- Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, et al Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study – a randomized controlled trial. JAMA 2003;289:2651–2662.
- Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, et al Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947–2958.
- Resnick SM, Espeland MA, Jaramillo SA, Hirsch C, Stefanick ML, Murray AM, Ockene J, Davatzikos C. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology 2009;72:135–142.
- Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279:688–695.
- Tan O, Harman SM, Naftolin F. What can we learn from design faults in the Women's Health Initiative randomized clinical trial? Bull NYU Hosp Jt Dis 2009;67:226–229.
- Nilsen J, Deng J, Brinton RD. Impact of clinically relevant progestins on the neural effects of estradiol and the signaling pathways involved. Drug News Perspect 2005;18:545–553.
- Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 2001;184:255–263.
- Darney PD. The androgenicity of progestins. Am J Med 1995;98:104S–110S.